Vascular endothelial growth factor and HDAC 6: A neuroprotective signalling pathway against cancer therapy-induced neuropathy

Brain

Volumn 135, Issue 9, 2012, Pages 2579-2580

  Garrido, Juan José ^a  

^a INSTITUTO CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA TUBULIN; BEVACIZUMAB; CALPAIN; CASPASE; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE 6; MEMBRANE PROTEIN; MOLECULAR MOTOR; MONOCLONAL ANTIBODY DC101; PACLITAXEL; SEMAXANIB; TUBULIN; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED POTASSIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL;

ACETYLATION; ALLODYNIA; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; BRAIN EDEMA; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CELL DIVISION; DRUG PROTEIN BINDING; ENZYME ACTIVATION; HUMAN; HYPERALGESIA; INFLAMMATION; MICROTUBULE; NEUROPATHY; NEUROPROTECTION; NONHUMAN; NOTE; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN TARGETING; SENSORIMOTOR FUNCTION; SIGNAL TRANSDUCTION;

EID: 84866402317     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aws227     Document Type: Note

References (13)

1. Carmeliet P, Storkebaum E. Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders. Semin Cell Dev Biol 2002; 13: 39-53.
2. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009; 6: 465-77.
3. Chen S, Owens GC, Makarenkova H, Edelman DB. HDAC6 regulates mitochondrial transport in hippocampal neurons. PLoS One 2010; 5: e10848.
4. Fukada M, Hanai A, Nakayama A, Suzuki T, Miyata N, Rodriguiz RM, et al. Loss of deacetylation activity of Hdac6 affects emotional behavior in mice. PLoS One 2012; 7: e30924.
5. Jaggi AS, Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology 2012; 291: 1-9.
6. Janke C, Bulinski JC. Post-translational regulation of the microtubule cytoskeleton: mechanisms and functions. Nat Rev Mol Cell Biol 2012; 12: 773-86.
7. Li G, Jiang H, Chang M, Xie H, Hu L. HDAC6 alpha-tubulin deacetylase: a potential therapeutic target in neurodegenerative diseases. J Neurol Sci 2011; 304: 1-8.
8. Mackenzie F, Ruhrberg C. Diverse roles for VEGF-A in the nervous system. Development 2012; 139: 1371-80.
9. Polomano RC, Mannes AJ, Clark US, Bennett GJ. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, pacli-taxel. Pain 2001; 94: 293-304.
10. Rao R, Fiskus W, Yang Y, Lee P, Joshi R, Fernandez P, et al. HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood 2008; 112: 1886-93.
11. Tapia M, Wandosell F, Garrido JJ. Impaired function of HDAC6 slows down axonal growth and interferes with axon initial segment development. PLoS One 2010; 5: e12908.
12. Verheyen A, Peeraer E, Nuydens R, Dhondt J, Poesen K, Pintelon I, et al. Systemic anti-vascular endothelial growth factor therapies induce a painful sensory neuropathy. Brain 2012; 135: 2629-2641.
13. von Hehn CA, Baron R, Woolf CJ. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron 2012; 73: 638-52.